Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a pre-clinical stage biotechnology company founded in 2019 and headquartered in Vancouver, Canada. The company went public in March 2021 and focuses on developing novel serotonin-based medicines for patients with severe neurological and psychiatric conditions. As a pre-clinical biotech firm, Bright Minds has not yet generated revenue from product sales and remains in the research and development phase of bringing potential treatments to market.
Latest newsMore news →